What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019

According to key diabetic studies, the early use of metformin glucose lowering therapy is associated with a reduced risk of developing micro- and, in the long term, 10-year follow-up, macrovascular complications and cardiovascular mortality. Short-term studies results on combined glucose lowering th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina V. Shestakova, Mikhail B. Antsiferov, Alexander S. Ametov, Gagik R. Galstyan, Tatiana Y. Demidova, Alexey V. Zilov, Tatiana N. Markova, Nina A. Petunina, Natalya A. Chernikova, Minara S. Shamkhalova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	diabetes mellitus vildagliptin metformin hba1c new onset diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/ce89e3c8673e4cb8b05e23404c86d100
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ce89e3c8673e4cb8b05e23404c86d100
record_format	dspace
spelling	oai:doaj.org-article:ce89e3c8673e4cb8b05e23404c86d1002021-11-14T09:00:23ZWhat are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 20192072-03512072-037810.14341/DM12404https://doaj.org/article/ce89e3c8673e4cb8b05e23404c86d1002020-04-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/12404https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378According to key diabetic studies, the early use of metformin glucose lowering therapy is associated with a reduced risk of developing micro- and, in the long term, 10-year follow-up, macrovascular complications and cardiovascular mortality. Short-term studies results on combined glucose lowering therapy with metformin suggests that combination therapy can have several advantages on the one side from the effectiveness of glycemic control and on another side from positive effect on the development of complications of type 2 diabetes. The question of the start time of combined hypoglycemic therapy remains open. According to the results of recent large-scale studies, real world evidence data, careful glycemic control during the first year from the moment of diagnosis of type 2 diabetes is crucial for further management of the disease and slow the progression of complications. However, due to the fact that the clinical benefits of early combination therapy were not demonstrated in randomized clinical trials, this approach, despite the theoretical background, was not recommended for widespread use in international guidelines for the treatment diabetes patients. Russian algorithms on the treatment diabetes patients recommend combined glucose lowering therapy at the start of treatment at a HbA1c level of 1% higher than the target. A 5-year VERIFY study results were demonstrated long-term sustained glycemic control in combination with vildagliptin + metformin prescribed for native diabetes patients with relatively low HbA1c values, as well as the advantages of this approach in comparison with the standard strategy for phased intensification of monotherapy. The results of the VERIFY study provided a wealth of information to discuss early treatment intensification, the clinical benefits of this approach and a possible review of the treatment strategy for native diabetes patients.Marina V. ShestakovaMikhail B. AntsiferovAlexander S. AmetovGagik R. GalstyanTatiana Y. DemidovaAlexey V. ZilovTatiana N. MarkovaNina A. PetuninaNatalya A. ChernikovaMinara S. ShamkhalovaEndocrinology Research Centrearticlediabetes mellitusvildagliptinmetforminhba1cnew onset diabetes mellitusNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 1, Pp 106-110 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes mellitus vildagliptin metformin hba1c new onset diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes mellitus vildagliptin metformin hba1c new onset diabetes mellitus Nutritional diseases. Deficiency diseases RC620-627 Marina V. Shestakova Mikhail B. Antsiferov Alexander S. Ametov Gagik R. Galstyan Tatiana Y. Demidova Alexey V. Zilov Tatiana N. Markova Nina A. Petunina Natalya A. Chernikova Minara S. Shamkhalova What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
description	According to key diabetic studies, the early use of metformin glucose lowering therapy is associated with a reduced risk of developing micro- and, in the long term, 10-year follow-up, macrovascular complications and cardiovascular mortality. Short-term studies results on combined glucose lowering therapy with metformin suggests that combination therapy can have several advantages on the one side from the effectiveness of glycemic control and on another side from positive effect on the development of complications of type 2 diabetes. The question of the start time of combined hypoglycemic therapy remains open. According to the results of recent large-scale studies, real world evidence data, careful glycemic control during the first year from the moment of diagnosis of type 2 diabetes is crucial for further management of the disease and slow the progression of complications. However, due to the fact that the clinical benefits of early combination therapy were not demonstrated in randomized clinical trials, this approach, despite the theoretical background, was not recommended for widespread use in international guidelines for the treatment diabetes patients. Russian algorithms on the treatment diabetes patients recommend combined glucose lowering therapy at the start of treatment at a HbA1c level of 1% higher than the target. A 5-year VERIFY study results were demonstrated long-term sustained glycemic control in combination with vildagliptin + metformin prescribed for native diabetes patients with relatively low HbA1c values, as well as the advantages of this approach in comparison with the standard strategy for phased intensification of monotherapy. The results of the VERIFY study provided a wealth of information to discuss early treatment intensification, the clinical benefits of this approach and a possible review of the treatment strategy for native diabetes patients.
format	article
author	Marina V. Shestakova Mikhail B. Antsiferov Alexander S. Ametov Gagik R. Galstyan Tatiana Y. Demidova Alexey V. Zilov Tatiana N. Markova Nina A. Petunina Natalya A. Chernikova Minara S. Shamkhalova
author_facet	Marina V. Shestakova Mikhail B. Antsiferov Alexander S. Ametov Gagik R. Galstyan Tatiana Y. Demidova Alexey V. Zilov Tatiana N. Markova Nina A. Petunina Natalya A. Chernikova Minara S. Shamkhalova
author_sort	Marina V. Shestakova
title	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
title_short	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
title_full	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
title_fullStr	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
title_full_unstemmed	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019
title_sort	what are new opportunities for clinical practice the verify study opens and which values for native diabetes patients? joint conclusion on the advisory board results. november 6, 2019
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/ce89e3c8673e4cb8b05e23404c86d100
work_keys_str_mv	AT marinavshestakova whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT mikhailbantsiferov whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT alexandersametov whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT gagikrgalstyan whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT tatianaydemidova whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT alexeyvzilov whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT tatiananmarkova whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT ninaapetunina whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT natalyaachernikova whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019 AT minarasshamkhalova whatarenewopportunitiesforclinicalpracticetheverifystudyopensandwhichvaluesfornativediabetespatientsjointconclusionontheadvisoryboardresultsnovember62019
_version_	1718429491156484096

What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019

Ejemplares similares